Kevin Cwach, MD
Urology · Urbandale, IANPI 1386037638
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,848 of the $7,170 with a category attached, or 67.6%. It is spread thinly across 31 manufacturers, the largest accounting for just 20.2%.
Across 125 payments — averaging $57.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$1K
- Procept Biorobotics Corporation$1K
- Medtronic$1K
- Boston Scientific$526
- Axonics, Inc.$451
- AbbVie$284
- plus $2K from 25 others
Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$355
What the payments were for
- Speaking & faculty fees$1031%
- Travel & lodging$1,97928%
- Food & beverage$4,84868%
- Education$1502%
- Gifts$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 8 | $1,451 |
| Procept Biorobotics Corporation | 10 | $1,356 |
| Medtronic | 21 | $1,315 |
| Boston Scientific | 8 | $526 |
| Axonics, Inc. | 8 | $451 |
| AbbVie | 11 | $284 |
| Sumitomo Pharma America, Inc. | 11 | $236 |
| Coloplast | 4 | $228 |
| Teleflex LLC | 2 | $174 |
| Astellas Pharma US Inc | 3 | $166 |
| Endo Pharmaceuticals Inc. | 9 | $151 |
| Johnson & Johnson | 2 | $132 |
| Ferring Pharmaceuticals Inc. | 5 | $112 |
| Accord Healthcare, Inc. | 2 | $93 |
| Caldera Medical, Inc | 1 | $89 |
| Dendreon Pharmaceuticals LLC | 2 | $62 |
| Urogen Pharma, Inc. | 2 | $51 |
| Rochester Medical Corporation | 2 | $50 |
| Olympus America Inc. | 1 | $28 |
| Endo USA, Inc. | 2 | $27 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| 180 Medical, Inc. | 1 | $21 |
| Immunitybio, Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Merck | 1 | $19 |
| Amgen | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Ambu Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,119
- eCoin Device Kit$1,041
- INTERSTIM$594
- Bulkamid$194
- ALTAVIVA$179
- UroLift$158
- Solyx SIS System$134
- LithoVue$121
- RYBREVANT$114
- CARVYKTI$114
- GEMTESA$103
- ADVANTAGE$101
- CONTINENCE CARE$100
How this compares
$7,170 in reported general payments places this provider in the 80th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 225 | $179,135 |
| MyrbetriqMirabegron | 126 | $114,868 |
| Tamsulosin Hcl | 494 | $7,480 |
| Estradiol | 82 | $4,949 |
| Methenamine Hippurate | 43 | $4,230 |
| Finasteride | 314 | $3,201 |
| Solifenacin Succinate | 54 | $2,058 |
| Trospium Chloride ErTrospium Chloride | 13 | $1,831 |
| Oxybutynin Chloride ErOxybutynin Chloride | 70 | $1,703 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $1,587 |
| Cephalexin | 115 | $625 |
| Oxybutynin Chloride | 19 | $609 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 36 | $547 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 27 | $541 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $236 | $179,135225 claims |
| Astellas Pharma US IncMyrbetriq | $166 | $114,868126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 urology providers in Iowa.
Other urology in Urbandale
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Kevin BirusinghDes Moines$59K
- Ryan DornbierClive$55K
- Alexandria HertzIowa City$53K
- John BuieIowa City$52K
- Charles SchlaepferIowa City$51K
- Mahmoud AlameddineOttumwa$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.